関連する実験動画
Updated: Jul 26, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
オステオサルコマの第一治療薬としての化学療法: 20年後の集団における有効性
M Gill1, M McCarthy, T Murrells
1Department of Community Medicine, University College London.
Lancet (London, England)
|March 26, 1988
まとめ
初次性骨肉腫の生存率は,より若い患者 (25歳未満) で境界線上の有意な改善を示しています. 病院での経験は結果に影響を与えるかもしれないが,化学療法はこの研究で独立して生存率を向上させなかった.
科学分野:
- 腫瘍学 腫瘍学
- エピデミオロジー エピデミオロジー
- バイオ統計学 バイオ統計学
背景:
- オステオサルコマは,主に子供や若者に発症する珍しい骨癌です.
- オステオサルコマの生存率は歴史的に変化しており,貢献する要因の調査を促しています.
- 人口ベースのデータは,現実世界の治療の有効性を理解するために不可欠です.
研究 の 目的:
- オステオサルコマの生存率の傾向を時間とともに調べる.
- 年齢,治療期間,化学療法,病院での経験など,生存に影響を与える要因を特定する.
- 治療の進歩が,骨肉腫患者のアウトカムに与える影響を評価する.
主な方法:
- 1963年から1984年の間に登録された原発性骨肉腫患者の5年生存コホートの分析.
- テムズ・ガン・レジストリからのデータを活用した.
- 生き残りの予測要因を評価するために,コックスの比例リスクモデルを使用した.
主要な成果:
- 25歳未満の患者では,生存率の限界的な有意な改善が観察されました (p=0.05).
- 若い患者の最新のコホート (p=0.02) で,生存率の改善の有意な傾向が認められた.
- 病院での治療経験は,若い患者のアウトカムとポジティブな関連性を示した (p=0.11),選択バイアスは考慮事項である. 化学療法は,どの年齢層でも生存率の改善と独立して関連していない.
結論:
- 若いオステオサルコマ患者の生存傾向の改善は,最近の臨床試験と患者の選択に関連している可能性があります.
- 集団ベースのがん登録データは,新しいがん治療法の有効性を検証するために不可欠です.
- オステオサルコマの長期的な生存改善を理解するために,さらなる研究とモニタリングが必要である.
関連する概念動画
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...